EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022

Rekha Tamatam, Dongyun Shin

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24065190 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Rekha Tamatam und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Gachon University, 191 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Republic of Korea. Hauptthemen laut MEDLINE: Proteins, Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) is a promising therapeutic modality that has garnered attention in academic, industrial, and pharmaceutical research for treating diseases such as cancer, neurodegenerative disorders, inflammation, and viral infections. In this context, proteolysis-targeting chimeras (PROTACs) present a reliable technology for degrading disease-causing proteins. PROTACs complement small-molecule inhibitors, which primarily rely on direct protein regulation. From concept-to-clinic, PROTACs have evolved from cell impermeable peptide molecules to orally bioavailable drugs. Despite their potential in medicinal chemistry, certain aspects regarding PROTACs remain unclear. The clinical significance of PROTACs is primarily limited owing to their lack of selectivity and drug-like properties. This review focused on recently reported PROTAC strategies, particularly in 2022. It aimed to address and overcome the challenges posed by classical PROTACs by correlating them with emerging approaches with improved selectivity and controllability, cell permeability, linker flexibility, druggability, and PROTAC-based approaches, developed in 2022. Furthermore, recently reported PROTAC-based approaches are discussed, highlighting each of their advantages and limitations. We predict that several improved PROTAC molecules will be accessible for treating patients exhibiting various conditions, including cancer, neurodegenerative disorders, inflammation, and viral infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteinsNeoplasmsHumansProteolysisUbiquitin-Protein Ligases

Stichwörter der Autor:innen

linker flexibilitypermeabilityproteolysis-targeting chimerasselectivitytargeted protein degradation

Substanzen

ProteinsUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • College of Pharmacy, Gachon University, 191 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Republic of Korea.
  • Gachon Pharmaceutical Research Institute, Gachon University, 191 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Republic of Korea.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Tamatam, R., & Shin, D. (2023). Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065190

Vancouver

Tamatam R, Shin D. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065190

BibTeX
@article{Tamatam2023,
  author = {Tamatam, Rekha and Shin, Dongyun},
  title = {Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24065190}
}
Kostenlos starten →